Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | GLA | P06280 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10939618 | 0.97 | CYP1A2 (0.75) | CYP1A2MAPK1SMN1; SMN2ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL1720619 | 0.97 | CYP1A2 (0.68) | CYP1A2MAPK1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL94068 | 0.97 | CYP1A2 (0.75) | CYP1A2MAPK1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL5313692 | 0.97 | CYP1A2 (0.75) | CYP1A2MAPK1SMN1; SMN2ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL1128098 | 0.95 | CYP1A2 (0.72) | CYP1A2MAPK1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL8202520 | 0.95 | CYP1A2 (0.72) | CYP1A2MAPK1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL3402164 | 0.95 | — | — | |
| Methylene Chloride SCHEMBL28294345 | 0.93 | CYP1A2 (0.63) | CYP1A2MAPK1SMN1; SMN2ALDH1A1MAPT | |
| Ethylene SCHEMBL27789472 | 0.93 | CYP1A2 (0.69) | CYP1A2MAPK1SMN1; SMN2ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL23886232 | 0.92 | GLA (0.65) | CYP1A2MAPK1SMN1; SMN2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 272 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017044411-A1 | METHODS AND COMPOSITIONS FOR SOFT ANTICHOLINERGIC ZWITTERIONS | BODOR LABORATORIES, INC. (US) | 2017-03-16 | — | — | WO | claimed |
| WO-2017040307-A1 | USE OF SELECTED ANTICHOLINERGIC ZWITTERIONS | BODOR LABORATORIES, INC. (US) | 2017-03-09 | — | — | WO | claimed |
| US-12624111-B2 | Methods for treating metastatic colon cancer with leronlimab | CYTODYN INC. (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4735418-A1 | LIPID COMPOUNDS FOR GENE DELIVERY AND USE THEREOF | Li, Bowen (CA) | 2026-05-06 | — | — | EP | disclosed |
| EP-3814356-B1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ZHEJIANG VIMGREEN PHARMACEUTICALS LTD (CN) | 2026-03-11 | — | — | EP | disclosed |
| US-20260060926-A1 | NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME | SAIL BIOMEDICINES INC (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4581012-A2 | NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME | Sail Biomedicines, Inc. (US) | 2025-07-09 | — | — | EP | disclosed |
| US-20250213593-A1 | Use of Derivatives based on Sarsasapogenin Structure and Pharmaceutical Compositions thereof | BEIJING PHYTOVENT PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2025-07-03 | — | — | US | disclosed |
| US-20250205167-A1 | NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME | SAIL BIOMEDICINES, INC. | 2025-06-26 | — | — | US | disclosed |
| CN-118265692-B | Carbon nucleus cationic lipid | 厦门赛诺邦格生物科技股份有限公司 | 2025-06-13 | — | — | CN | disclosed |
| EP-4559896-A1 | PH-SENSITIVE CATIONIC LIPID AND LIPID NANOPARTICLE | National University Corporation Hokkaido University (JP) | 2025-05-28 | — | — | EP | disclosed |
| CN-1010096-B | CHARTREUSIN DERIVATIVE AND ITS SALT, ANTITUMOROUS PREPARATIONS CONTAINING THE SAME, AS WELL PROCESS FOR MAKING THE PREPARATION | ISHIHARA SANGYO KAISHA (JP) | 1990-10-24 | — | — | CN | disclosed |
| US-4927919-A | ANTITUMOR AGENTS | ISHIHARA SANGYO KAISHA, LTD. (JP) | 1990-05-22 | — | — | US | disclosed |
| WO-1989009775-A1 | N-HETEROCYCLIC PROPYLIDENE-1,1-BISPHOSPHONIC ACIDS, THEIR PRODUCTION AND A PHARMACEUTICAL COMPOSITION | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LØVENS KEMIS (DK) | 1989-10-19 | — | — | WO | disclosed |
| US-4760136-A | Chartreusin derivatives and salts thereof | ISHIHARA SANGYO KAISHA, LTD. (JP) | 1988-07-26 | — | — | US | disclosed |
| US-4719176-A | Enzyme-free diagnostic binding reagents | KLOTZ IRVING M (US) | 1988-01-12 | — | — | US | disclosed |
| EP-0110575-B1 | 1-AROYL-5-OXO-2-PYRROLIDINEPROPANOIC ACIDS AND RELATED ESTERS | WARNER-LAMBERT COMPANY (US) | 1987-05-20 | — | — | EP | disclosed |
| EP-0219852-A2 | Chartreusin derivatives, salts thereof, antitumorous compositions containing the same, and processes for producing the same | ISHIHARA SANGYO KAISHA, LTD. (JP) | 1987-04-29 | — | — | EP | disclosed |
| CN-85103287-A | Chartreusin (Chartreusin) derivative and its salt contain the anti-tumor compositions of these compounds, and the method for preparing these compounds | — | 1987-02-04 | — | — | CN | disclosed |
| EP-0089926-A2 | Pharmaceutical preparations of tetracycles containing nitrogen, and compounds of this type | CIBA-GEIGY AG (CH) | 1983-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250205167-A1 | NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME | PHOSPHO1, SGMS2, SGMS1 | CYP1A2 4843/4885MAPK1 4424/4885SMN1; SMN2 2439/4885 |
| US-12624111-B2 | Methods for treating metastatic colon cancer with leronlimab | CCR5, CCL2, CCR2 | CYP1A2 2974/4885MAPK1 465/4885SMN1; SMN2 4160/4885 |
| US-20260060926-A1 | NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME | SGMS1, NPC1L1, SGMS2 | CYP1A2 4683/4885MAPK1 1940/4885SMN1; SMN2 1074/4885 |
| US-20250213593-A1 | Use of Derivatives based on Sarsasapogenin Structure and Pharmaceutical Compositions thereof | MAVS, NLN, TFAM | CYP1A2 2086/4885MAPK1 3031/4885SMN1; SMN2 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.